Screening for hepatocellular carcinoma

Journal of the College of Physicians and Surgeons Pakistan

Volumn 14, Issue 9, 2004, Pages 570-575

  Parvez, Tariq ^e   Parvez, Babar ^b   Pervaiz, Khurram ^a   Gumgumji, Abbass Ali ^c   Al Ahmadi, Saleem ^d   Sabir, Akbar Ali ^e   Khawaja, Fazal Imtiaz ^c  

^a Pakistan Soc for Cancer Prevention   (Pakistan)

^b Babar Clinic   (Pakistan)

^c Department of Gastroenterology   (Saudi Arabia)

^d KFH   (Saudi Arabia)

^e KING FAHAD HOSPITAL   (Saudi Arabia)

Author keywords

Alpha fetoprotein; Cirrhosis; Hepatitis C; Hepatits B; Magnetic resonance imaging; Spiral CT scan; Ultrasonography

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER;

ANGIOGRAPHY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL PROTOCOL; COMMUNITY CARE; COMPUTER ASSISTED DIAGNOSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY DIAGNOSIS; ECHOGRAPHY; ECONOMIC EVALUATION; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MASS SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; REVIEW; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT PLANNING;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; HUMANS; LIVER NEOPLASMS;

EID: 5044243791     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Parvez T, Anwar SM. HBsAg and hepatocellular carcinoma more common in lower socio-economical class: our experience. J Coll Physicians Surg Pak 2001; 11: 669-71.
2. Parvez T, Gumgumji AA, Raddadi MA, Rufai AA, Sabir AA, Ibraheim MI. Hepatocellular carcinoma: available diagnostic tools and their limitations. J Coll Physicians Surg Pak 2004; 14: 57-60.
3. Global action against cancer. New from UICC and WHO. Globocan IARC 2000.
4. Nagao Y, Tanaka K, Kobayashi K, Kumashiro R, Sata M. A cohort study of chronic liver disease in an HCV hyperendemic area of Japan: a prospective analysis for 12 years. Int J Mol Med 2004; 13: 257-65.
5. Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35 (5 Suppl 2): S86-91.
6. Choi BI. The current status of imaging diagnosis of hepatocellular carcinoma. Liver Transpl 2004; 10 (2 suppl 1): S20-5.
7. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10 (2 suppl 1): S115-20.
8. American Cancer Society: Can cancer be found early? Cancer reference information, 2001 [cited 2002 June 24] Available from URL:http://www.cancer.org/eprise/main/docroot/CRI/content/
9. Hulka BS. Cancer screening. Degrees of proof and practical application. Cancer 1988; 62: 1776-80.
10. Hurley SF, Kaldor JM. The benefits and risks of mammographic screening for breast cancer. Epidemiol Rev 1992; 14: 101-30.
11. Parkin DM, Moss SM. Cancer screening. Improved survival but no reduction in deaths: the role of over diagnoses. Cancer 2000; 89: 2369-76.
12. Greenberg R, Daniels S, Flanders D. Medical epidemiology. Norwalk. Appleton & Lange 1993.
13. Ellman R. Clinical cost-benefit of screening programs. In: Stoll B, (edi). Women at high risk to breast cancer. Boston: Kluwer Academic Publishers; 1991.
14. Thornton H. Pairing accountability with responsibility, the consequences of screening 'promotion'. Med Sci Monit 2001; 7: 531-3.
15. Schwartz JM, Ham JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2003; 6: 465-72.
16. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25:259.
17. Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39: 208.
18. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273.
19. Wu JT. Serum alpha-fetoprotein and its lectin reactivity in liver disease: a review. Ann Clin Lab Sci 1990; 20: 98.
20. Lok AS, Lai CL. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9: 110.
21. Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, et al. Serum alpha-fetoprotein in early stages of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-9.
22. Fasani P, Sangiovanni A, De Fazio C, Borzio M, Bruno S, Ronchi G, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999; 29: 1704-7.
23. Soreide O, Czerniak A, Bradpiece H, Bloom S, Blumgart L. Characteristics of fibrolamellar hepatocellular carcinoma: a study of nine cases and review of the literature. Am J Surg 1986; 151: 518-23.
24. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
25. Parvez T, Anwar SM. Diagnostic value of AFP in liver cancer. J Coll Physicians Surg Pak 2001; 11: 431-3.
26. Parvez T, Anwar SM. Diagnostic value of different tumor markers, our experience. J Coll Physicians Surg Pak 2000; 10: 418-20.
27. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432.
28. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139:46.
29. Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77: 1781-6.
30. Marrero JA, Su GL, Wei W, Emick O, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114.
31. Tsai FJ, Jeng JE, Chuang LY. Clinical evaluation of urinary transforming growth factor beta1 and serum alpha-fetoprotein as tumor markers of hepatocellular carcinoma. Br J Cancer 1997; 75: 1460.
32. Hamazaki K, Gochi A, Shimamura H, Kaihara A, Maruo Y, Doi Y, et al. Serum levels of circulating intercellular adhesion molecule 1 in hepatocellular carcinoma. Hepatogastroenterology 1996; 43: 229.
33. Benvegnu L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A. Evidence for an association between the etiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48: 110-5.
34. Ishiguchi T, Shimamoto K, Fukatsu H, Yamakawa K, Ishigaki T. Radiological diagnosis of hepatocellular carcinoma. Semin Surg Oncol 1996; 12: 164-9.
35. Larcos G, Sorokopud H, Berry G, Farrell GC. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol 1998; 171: 433.
36. Hayakawa S, Goto H, Hirooka Y, Itoh A, Taki T, Watanabe Y, et al. Colour doppler-guided spectral analysis of gall-bladder wall flow. J Gastroenterol Hepatol 1998; 13: 181-5.
37. Hollett MD, Jeffrey RB Jr, Nino-Murcia M, Jorgensen MJ, Harris DP. Dual-phase helical CT of the liver: Value of arterial phase scans in the detection of small (<1.5 cm) malignant hepatic neoplasms. AJR Am J Roentgenol 1995; 164: 879-84.
38. Ngan H. Lipiodol computerized tomography: how sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? Br J Radiol 1990; 63:771.
39. Lim JH, Choi D, Kim SH, Lee SJ, Lee WJ, Lim HK, et al. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol 2002; 179:67.
40. Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. AJR Am J Roentgenol 2003; 180:441.
41. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, et al, Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8:749.
42. Yu, JS, Kim, KW, Lee, JT, Yoo, HS. MR imaging during arterial portography for assessment of hepatocellular carcinoma: comparison with CT during arterial portography. AJR Am J Roentgenol 1998; 170: 1501.
43. Choi D, Kim S, Lim J, Lee W, Jang H, Lee S, et al. Pre-operative detection of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus combined helical CT during arterial portography and CT hepatic arteriography. AJR Am J Roentgenol 2001; 176: 475-83.
44. Dresel S, Kirsch CM, Tatsch K, Zachoval R, Hahn K, Goldenberg DM. Detection of hepatocellular carcinoma with a new alpha-feto-protein antibody imaging kit. J Clin Oncol 1997; 15: 2683-90.
45. Bru C, Maroto A, Bruix J, Faus R, Bianchi L, Calvet X, et al. Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. Dig Dis Sci 1989; 34:1765-9.
46. Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001; 35: 254-8.
47. Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, et al. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without pre-operative treatments. Cancer 1996; 77: 2022-31.
48. Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003; 9: 672.
49. McMahon BJ, Alberts SR, Wainwright RB. Prospective study of 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150:1051
50. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Takada A, Fukumori K, et al. Diagnostic clues for recurrent hepatocellular carcinoma: comparison of tumor markers and imaging studies. Eur J Gastroenterol Hepatol 2003; 15: 641-8.
51. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330.
52. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842-6.
53. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61.
54. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520.
55. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942.
56. Ebara M, Ohto M, Shinagawa T, Sugiura N, Kimura K, Matsutani S, et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. Gastroenterology 1986; 90: 289-98.
57. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98: 679-90.
58. Parvez T, Anwar SM. Other etiological factors besides HBV responsible for HCC in lower social class: our experience. J Coll Physicians Surg Pak 2002; 12: 268-70.
59. Longmore M, Wilkinson I, Torok E. Oxford handbook of clinical medicine. Oxford. Oxford University Press 2001; 220.